1Jain KK. Neuroprotection in cerebrovascular disease. Expert Opin Investig Drugs, 2000,9:695
2Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nippon Yakurigaku Zasshi, 2002, 119:301
3Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 2003, 15:222
4Tabrizchi R. Edaravone Mitsubishi-Tokyo. Curr Opin Investig Drugs, 2000,1:347
5Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res, 2002,43:75
6Tanahashi N, Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern Med, 2002, 41:337
7Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCJ-186), on acute brain infarction.Randomized, lacebo-controlled, double-blind study at multicenters.Cerebrovasc Dis, 2003, 15: 222 - 229.
8Takamatsu Y, Yuki S, Watanabe T. Studies on the concentration of 3 -methyl-1-1 phenyl-2-pyrazolin-5 -one (MCI-186) in MCA occlusion and reperfusion model of rats. Jpn Pharmacol Ther, 1997, 25(Suppl): S1785 - S1791.
9Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res, 2002, 43:75 -79.
10Felberg RA, Burgin WS, Grotta JC. Neuroprotection and the ischemic cascade. CNS Spectrums, 2000, 5:52 -58.
